DNA damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status
These findings highlight T-DXd's effectiveness in HER2-low and HRD tumors, supporting its broader clinical application, including strategies targeting DNA damage repair pathways.
Authors
- Jiwon Koh (ORCID: https://orcid.org/0000-0002-7687-6477)
- Dae‐Won Lee (ORCID: https://orcid.org/0000-0001-7133-6669)
- Sujin Ham
- So Hyeon Kim (ORCID: https://orcid.org/0009-0002-9279-4225)
- Seongyeong Kim
- Hye Yeon Park
- Ahrum Min (ORCID: https://orcid.org/0000-0003-3236-838X)
- Han Suk Ryu (ORCID: https://orcid.org/0000-0003-2508-9796)
- Jin‐Soo Kim (ORCID: https://orcid.org/0000-0003-4847-1306)
- Yu‐Jin Kim (ORCID: https://orcid.org/0000-0003-2562-615X)
- Young Joo Park (ORCID: https://orcid.org/0000-0002-3671-6364)
- Seock Ah Im
- Kyung-Hun Lee
Institutions
- Seoul National University (KR)
- Seoul Metropolitan Government (KR)
- Seoul National University Hospital (KR)
- SNUH SMG-SNU Boramae Medical Center (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-08-04
- DOI
- https://doi.org/10.4143/crt.2025.201
- Citations
- 1
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 1.36